Zynext Ventures USA LLC (Zynext Ventures), the venture capital arm of Zydus Lifesciences (Zydus), announced its investment in Illexcor Ther...
GC Cell, under the leadership of CEO Sungyong Won, announced the initiation of its domestic Phase 1 clinical trial for GCC2005 (AB‑205), a novel CD5...
Akeso, Inc. is excited to announce that the groundbreaking results of the Phase III clinical study (HARMONi-2/AK112-303) of its first-in-class PD-1/VE...
BeiGene, Ltd. a global oncology company that intends to change its name to BeOne Medicines Ltd., announced the U.S. Food and Drug Administr...
Tenosynovial giant cell tumor, also known as pigmented villonodular synovitis (PVNS) or giant cell tumor of the tendon sheath (GCT-TS), is primarily treate...
CStone Pharmaceuticals, an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, announced that&nbs...
CARsgen Therapeutics Holdings Limited, a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors,...
Alumis Inc. (“Alumis” or the “Company”), a clinical stage biopharmaceutical company developing oral therapies using a precision app...
Inventiva ("Inventiva" or the "Company"), a clinical-focused biopharmaceutical company focused on the development of orally administered small molecules fo...
Telix Pharmaceuticals Limited announces that the United States (U.S.) Food and Drug Administration (FDA) has accepted the Biologics License...
Miltenyi Biotec, a global leader in cell and gene therapy solutions, has inaugurated a cutting-edge Cell & Gene Therapy Center in Genome Valley...
Harvard Bioscience, Inc. will present its latest product innovations at the Society of Toxicology (SOT) conference, further advancing preclinical research ...
Akeso, Inc. ("Akeso" or the "Company") announced that its partner on ivonescimab, Summit Therapeutics Inc. has entered into a clinical trial collabor...
Regeneron Pharmaceuticals, Inc. announced updated data for the investigational gene therapy DB-OTO from the Phase 1/2 CHORD trial in 12 children who have p...
© 2025 Biopharma Boardroom. All Rights Reserved.
